Diabetes, Metabolic Syndrome and Obesity (Sep 2019)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes

  • Ito H,
  • Matsumoto S,
  • Izutsu T,
  • Kusano E,
  • Nishio S,
  • Antoku S,
  • Yamasaki T,
  • Mori T,
  • Togane M,
  • Ando S,
  • Tsugami E

Journal volume & issue
Vol. Volume 12
pp. 1783 – 1794

Abstract

Read online

Hiroyuki Ito1, Suzuko Matsumoto1, Takuma Izutsu1, Eiji Kusano1, Shinya Nishio1, Shinichi Antoku1, Tomoko Yamasaki1, Toshiko Mori1, Michiko Togane1, Shigenori Ando2, Emiko Tsugami2 1Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo, Japan; 2Department of Pharmacy, Edogawa Hospital, Tokyo, JapanCorrespondence: Hiroyuki ItoDepartment of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, 2-24-18, Higashikoiwa, Edogawa-ku, Tokyo 133-0052, JapanTel +81 3 3673 1221Fax +81 3 3673 1229Email [email protected]: The factors associated with the renal prognosis over six months after the initiation of empagliflozin were compared between the non-elderly and elderly Japanese patients with type 2 diabetes.Patients and methods: In total, 132 patients treated with empagliflozin (10 mg, once daily) were studied as the safety analysis set. One hundred ten subjects whose medications were not changed during the observation period were investigated as the full analysis set to assess the effectiveness. The subjects were divided into two groups: non-elderly subjects (n=72) of<65 years of age and elderly subjects (n=38) of≥65 years of age.Results: Although the body weight and HbA1c, AST, ALT and γ-GTP levels were significantly reduced in both the non-elderly and elderly subjects, blood pressure, eGFR and urinary protein excretion were only significantly decreased in the non-elderly subjects. The hemoglobin, hematocrit and serum HDL-cholesterol levels were significantly elevated in both groups. The change in eGFR showed a significant positive association with the change in blood pressure. The change in urinary protein excretion tended to be correlated with the change in blood pressure.Conclusion: Although renoprotective effects might be limited, empagliflozin can safely and effectively improve metabolic parameters, even in elderly subjects.Keywords: sodium-glucose cotransporter 2 inhibitor, empagliflozin, type 2 diabetes mellitus, elderly, renoprotection, renal impairment

Keywords